Aquabounty Technologies Inc: Form 10-Q for the period ended Mar 31, 2024
Filed with the SEC on May 15, 2024 and accepted by EDGAR at May 15, 2024, 08:16 ET.
Management's discussion and analysis
As filed, 17,902 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on April 1, 2024.
Overview
We believe that we are a distinctive brand in the field of land-based aquaculture, leveraging decades of technology expertise to deliver innovative solutions that address food insecurity and climate change issues, while improving efficiency and sustainability. We raise our fish in carefully monitored land-based fish farms through a safe, secure and sustainable process. Our land-based recirculating aquaculture system farms, including our broodstock and egg production farm located on Prince Edward Island in Canada, are close to key consumption markets and are designed to prevent disease and to include multiple levels of fish containment to protect wild fish populations. We raise nutritious salmon that is free of antibiotics and other contaminants and provides a solution with a reduced carbon footprint without the risk of pollution to marine ecosystems as compared to traditional sea-cage farming. Our primary product is our GE Atlantic salmon, which received FDA approval in 2015 as the first genetically engineered animal available for sale for human consumption. We commenced commercial activities in 2021 with operations in the United States and Canada. We are actively engaged in genetic, genomic, fish health and fish nutrition research, which drive continuous improvement in our operations and may lead to new, disruptive technologies and products that could further expand our competitive offerings.
Company Update
We have been pursuing a growth strategy that includes the construction of large-scale recirculating aquaculture system farms for producing our GE Atlantic salmon. Our farm in Pioneer, Ohio is under construction and roughly 30% complete, but construction activities have been paused. To fund the construction cost, we were using cash on hand, which would be supplemented by a municipal bond financing. However, during the initial two years of construction, the cost estimate for the farm increased substantially and eventually exceeded our ability to complete the proposed financing. Consequently, we require new financing to provide liquidity for working capital and to fund the construction of our farm in Pioneer, Ohio. To meet this need, we have engaged an investment bank to pursue a range of funding and strategic alternatives, including the recently announced sale process for our Indiana farm, debt financing secured by our unencumbered assets, and potential joint venture partnerships or other strategic transactions.
Inflation
Recently elevated global inflation rates continue to impact all areas of our business. We are experiencing higher costs for farming supplies, transportation costs, wage rates, and other direct operating expenses, as well as for capital expenditures related to the construction of our farm in Ohio. We expect inflation to continue to negatively impact our results of operations for the near-term.
Financial Overview
We expect our future capital requirements will be substantial, particularly as we continue to develop our business and expand our commercial activities.
Product Revenue
We have generated product revenue primarily through the sales of our GE Atlantic salmon, supplemented by sales of conventional Atlantic salmon, salmon eggs, fry, and byproducts. With the expected sale of our Indiana farm, our product revenues will consist of conventional Atlantic salmon eggs and fry for the near term.
Product Costs
Product costs include the labor and related costs to grow out our fish, including feed, oxygen, and other direct costs; overhead; and the cost to process and ship our products to customers. A portion of production costs is absorbed into inventory as fish in process to the extent that these costs do not exceed the net realizable value of the fish biomass. The costs that are not absorbed into inventory, as well as any net realizable value inventory adjustments, are classified as product costs. Our product costs also include the labor and related costs to maintain our salmon broodstock. During the three months ended March 31, 2024, we recognized $1.0 million of product cost to reduce the value of our Indiana farm inventory in conjunction with its planned sale.
Sales and Marketing Expenses
Our sales and marketing expenses currently include salaries and related costs for our sales personnel and agency fees for market-related activities.
Research and Development Expenses
We recognize research and development expenses as they are incurred. Our research and development expenses consist primarily of salaries and related overhead expenses for personnel in research and development functions; fees paid to contract research organizations and consultants who perform research for us; and costs related to laboratory supplies used in our research and development efforts.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and related costs for employees in executive, corporate, and finance functions. Other significant general and administrative expenses include corporate governance and public company costs, regulatory affairs, rent and utilities, insurance, and legal services.
Long-Lived Asset Impairment
In February 2024, we commenced a process to identify a potential buyer for our Indiana farm. This decision was determined to be an impairment triggering event for long-lived assets at the Indiana farm, resulting in the impairment of $4.3 million of long-lived assets. As of March 31, 2024, the Indiana farm was not available for immediate sale in its present condition, as we need to complete additional system shut down processes. Therefore, the related long-lived assets continued to be classified as held in use.
Other Expense
Interest expense includes the interest on our outstanding loans and other interest expense. Other expense includes bank charges, fees, and interest income.
Results of Operations
Comparison of the three months ended March 31, 2024, to the three months ended March 31, 2023
The following table summarizes our results of operations for the three months ended March 31, 2024 and 2023, together with the changes in those items in dollars and as a percentage (all dollar amounts in thousands):
(unaudited)
| Three Months Ended March 31, 2024 | 2023 | Dollar% Change | Change | |
|---|---|---|---|---|
| Product revenue | $477 | $398 | 79 | 20% |
| Operating expenses: | ||||
| Product costs | 4,476 | 3,559 | 917 | 26% |
| Sales and marketing | 64 | 198 | (134) | (68)% |
| Research and development | 120 | 123 | (3) | (2)% |
| General and administrative | 2,500 | 3,001 | (501) | (17)% |
| Long-lived asset impairment | 4,265 | - | 4,265 | —% |
| Operating loss | 10,948 | 6,483 | 4,465 | 69% |
| Total other expense | (210) | (3) | (207) | 6,900% |
| Net loss | $11,158 | $6,486 | 4,672 | 72% |
Product Revenue
(unaudited)
| Three Months Ended March 31,% 2024 | 2023 | Change | Change | |
|---|---|---|---|---|
| Harvest of GE Atlantic salmon (mt) | 415 | 66 | 349 | 529% |
| Product revenue | ||||
| GE Atlantic salmon revenue | $395 | $392 | $3 | 1% |
| Non-GE Atlantic salmon revenue | 80 | 2 | 78 | 3,900% |
| Other revenue | 2 | 4 | (2) | (50)% |
| Total product revenue | $477 | $398 | $79 | 20% |
13
The increase in revenue during the current period was primarily due to an increase in the sale of conventional Atlantic salmon, fry and eggs from our Rollo Bay farm. Harvest volume of our GE Atlantic salmon was up substantially, as we prepared our Indiana farm for sale. An accelerated harvesting schedule at the Indiana farm required harvesting predominantly below-market sized fish, which impacted the average selling price for the current period.
Product Costs
Product costs for the three months ended March 31, 2024, were up from the corresponding period in 2023, primarily due to costs associated with the winding down of operations at the Indiana farm, including a net realizable value adjustment of $900 thousand against its biomass inventory, and a $100 thousand reserve against its feed inventory. Net of these charges, product costs were lower in the current period.
Sales and Marketing Expenses
Sales and marketing expenses for the three months ended March 31, 2024, were down from the corresponding period in 2023 due to decreases in personnel costs, marketing programs, travel, and share-based compensation costs.
Research and Development Expenses
Research and development expenses for the three months ended March 31, 2024, were down from the corresponding period in 2023, primarily due to decreases in project spending.
General and Administrative Expenses
General and administrative expenses for the three months ended March 31, 2024, were down from the corresponding period in 2023 due to reductions in professional services, state excise tax liabilities, share-based compensation costs, and travel, offset by increases in personnel costs and legal fees.
Long-Lived Asset Impairment
An asset impairment charge of $4.3 million was incurred in the current period against the long-lived assets of the Indiana farm. We determined the impairment charge, based on the estimate of the potential market value of the asset group to be sold, net of selling costs, compared to the current net book value of those assets.
Total Other Expense
Total other expense is comprised of interest expense and bank charges, less interest income for the three months ended March 31, 2024 and 2023.
Cash Flows
The following table sets forth the significant sources and uses of cash for the periods set forth below (in thousands):
(unaudited)
| Net cash (used in) provided by: | Three Months Ended March 31, 2024 | 2023 | Dollar% Change | Change |
|---|---|---|---|---|
| Operating activities | $(4,372) | $(6,142) | 1,770 | (29)% |
| Investing activities | (1,169) | (22,935) | 21,766 | (95)% |
| Financing activities | (67) | 215 | (282) | (131)% |
| Effect of exchange rate changes on cash | (3) | - | (3) | —% |
| Net change in cash | $(5,611) | $(28,862) | 23,251 | (81)% |
14
Cash Flows from Operating Activities
Net cash used in operating activities during the three months ended March 31, 2024, was primarily comprised of our $11.2 million net loss, partially offset by non-cash depreciation and share-based compensation charges of $681 thousand, a long-lived asset impairment charge of $4.3 million and decreased by working capital sources of $1.8 million. Net cash used in operating activities during the three months ended March 31, 2023 was primarily comprised of our $6.5 million net loss, offset by non-cash depreciation and share-based compensation charges of $728 thousand, and increased by working capital uses of $388 thousand.
Spending on operations decreased in the current period, before the recording of impairment charges against the Indiana farm property and inventory assets, due to reductions in marketing programs, outside research projects, professional services, and share-based compensation. Increases in cash provided by working capital was due to reductions in inventory and other current assets and increases in accounts payable and accrued expenses.
Cash Flows from Investing Activities
During the three months ended March 31, 2024 and 2023, we used $1.2 million and $22.9 million, respectively for construction activities at our farm sites and the purchase of equipment.
Cash Flows from Financing Activities
During the three months ended March 31, 2024, we received $117 thousand from new debt and made $184 thousand in debt repayments. During the same period in 2023, we received $394 thousand from new debt and made $179 thousand in debt repayments.
Future Capital Requirements
Since inception, we have incurred cumulative net losses and negative cash flows from operating activities and we expect this to continue for the foreseeable future. As of March 31, 2024, we had $3.6 million of cash, cash equivalents, and restricted cash. Our ability to continue as a going concern is dependent upon our ability to raise additional capital, and there can be no assurance that such capital will be available in sufficient amounts, on a timely basis, on terms acceptable to us, or at all. This raises substantial doubt about our ability to continue as a going concern within one year after the date that the accompanying condensed consolidated financial statements are issued.
On April 18, 2024, we entered into a Loan Agreement with JMB Capital Partners Lending, LLC to fund working capital through a secured term loan of up to $10 million that matures on July 31, 2024 or, if earlier, upon the sale of certain collateral or upon an Event of Default (as defined in the Loan Agreement) . Of the total loan amount, $5 million was advanced on April 18, 2024, and an additional $5 million will be advanced upon the satisfaction of certain conditions set out in the Loan Agreement. The loan bears interest at a rate of 15% on its outstanding principal balance and is subject to a commitment fee equal to 5%, payable at closing, and an exit fee equal to 8%. Of the initial loan advancement, approximately $2.8 million was used to pay the remaining outstanding balance of the Company’s term loan with First Farmers Bank & Trust, upon which the $1 million of restricted cash held by the Company as of both March 31, 2024 and December 31, 2023, was no longer deemed to be restricted.
Until such time, if ever, as we can generate positive cash flows from operating activities, we may finance our cash needs through a combination of equity offerings, debt financings, government or other third-party funding, strategic alliances, and licensing arrangements, as well as our announced plan to sell our Indiana farm. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of holders of our common stock will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements, or other collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or to grant licenses on terms that may not be favorable to us.
If we are unable to generate additional funds in a timely manner, we will exhaust our resources and will be unable to maintain our currently planned operations. If we cannot continue as a going concern, our stockholders would likely lose most or all of their investment in us.
Critical Accounting Policies and Estimates
This Management’s Discussion and Analysis of Financial Condition and Results of Operations is based on our condensed consolidated financial statements, which we have prepared in accordance with GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.
There have been no material changes to these estimates, or the policies related to them, during the three months ended March 31, 2024. For a full discussion of these estimates and policies, see “Critical Accounting Policies and Estimates” within “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023.
Smaller Reporting Company Status
We are a “smaller reporting company,” meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million.
As a smaller reporting company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and smaller reporting companies have reduced disclosure obligations regarding executive compensation.
Market risk
As filed, 1,466 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following sections provide quantitative information on our exposure to interest rate risk and foreign currency exchange risk. We make use of sensitivity analyses, which are inherently limited in estimating actual losses in fair value that can occur from changes in market conditions.
Interest Rate Risk
Our primary exposure to market risk is interest rate risk associated with debt financing that we utilize from time to time to fund operations or specific projects. The interest on this debt is usually determined based on a fixed rate and is contractually set in advance. As of March 31, 2024 and December 31, 2023, we had $4.5 million and $4.6 million, respectively, in interest-bearing debt instruments on our consolidated balance sheet. All of our interest-bearing debt is at fixed rates.
Foreign Currency Exchange Risk
Our functional currency is the U.S. Dollar. The functional currency of our Canadian subsidiary is the Canadian Dollar, and the functional currency of our U.S. and Brazil subsidiaries is the U.S. Dollar. For the Canadian subsidiary, assets and liabilities are translated at the exchange rates in effect at the balance sheet date, equity accounts are translated at the historical exchange rate, and the income statement accounts are translated at the average rate for each period during the year. Net translation gains or losses are adjusted directly to a separate component of other comprehensive loss within stockholders’ equity.
Controls and procedures
As filed, 1,750 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is: (1) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. As of March 31, 2024 (the “Evaluation Date”), our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our Chief Executive Officer and Chief Financial Officer have concluded, based upon the evaluation described above that, as of the Evaluation Date, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) for the quarter ended March 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 3,751 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
As disclosed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on April 1, 2024, there are a number of risk factors that could affect our business, financial condition, and results of operations. The following risk factors are either new or have changed materially from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2023. In evaluating our business, you should carefully review the risks described in our Annual Report on Form 10-K, including our consolidated financial statements and related notes, and in other reports we file with the SEC. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition, or prospects. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment.
This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks faced by us described below, elsewhere in this Quarterly Report on Form 10-Q, and in our Annual Report on Form 10-K. See “Cautionary Note Regarding Forward-Looking Statements” for information relating to these forward-looking statements.
We have a history of net losses and will likely incur future losses and may not achieve or maintain profitability.
In the period from incorporation to March 31, 2024, we have incurred cumulative net losses of approximately $232 million. These losses reflect our personnel, research and development, production and marketing costs. Our ability to realize revenues and the timing thereof are not certain, and achieving revenues does not assure that we will become profitable. We anticipate incurring additional losses until such time that we can generate significant increases to our revenues, and/or reduce our operating costs and losses. The size of our future net losses will depend, in part, on the rate of future expenditures and our ability to significantly grow our business and increase our revenues. We expect to continue to incur substantial and increased expenses as we grow our business. We also expect a continued increase in our expenses associated with our operations as a publicly traded company.
There is substantial doubt about our ability to continue as a going concern.
Since inception, we have incurred cumulative net losses and negative cash flows from operations and expect that this will continue for the foreseeable future. As of March 31, 2024, we had $3.6 million in cash and cash equivalents, and restricted cash.
Our ability to continue as a going concern is dependent upon our ability to raise additional capital, and there can be no assurance that such capital will be available in sufficient amounts, on a timely basis, on acceptable terms, or at all. This raises substantial doubt about our ability to continue as a going concern within one year after the date hereof. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of this uncertainty. Until such time as we reach profitability, we will require additional financing to fund our operations and execute our business plan. If we cannot continue as a going concern, our stockholders would likely lose most or all of their investment in us.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-01-01 to 2024-03-31 | $477.3k | us-gaap:Revenues |
| Research and development | 3 months2024-01-01 to 2024-03-31 | $119.8k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-01-01 to 2024-03-31 | −$10.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-01-01 to 2024-03-31 | $208.6k | us-gaap:InterestExpense |
| Income tax | 3 months2024-01-01 to 2024-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-01-01 to 2024-03-31 | −$11.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-01-01 to 2024-03-31 | −$2.90 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-01-01 to 2024-03-31 | −$2.90 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-01-01 to 2024-03-31 | 3,849,248 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2024-01-01 to 2024-03-31 | −$4.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2024-01-01 to 2024-03-31 | $1.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-03-31 | $2.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $4.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $176.2m | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $16.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-03-31 | $22.3m | us-gaap:Liabilities |
| Long-term debt | At period end2024-03-31 | $5.3m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-03-31 | $3.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-03-31 | $153.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001603978-24-000036. Last ingested by Listed: Nov 6, 2026, 16:32 ET. Listed shows no prices and gives no investment advice.